Leah Harvey1, Jessica L Taylor, Sabrina A Assoumou, Jessica Kehoe, Elissa M Schechter-Perkins, Edward Bernstein, Alexander Y Walley. 1. Department of Medicine, Section of Infectious Diseases, Boston University School of Medicine and Boston Medical Center, Boston, MA (LH, SAA); Department of Medicine, Section of General Internal Medicine, Boston University School of Medicine and Boston Medical Center, Boston, MA (JLT, AYW); Boston Medical Center, Boston, MA (JK) and Department of Emergency Medicine, Boston University School of Medicine, Boston, MA (EMSP, EB).
Abstract
OBJECTIVE: To study the infection-related needs of patients with substance use disorders initiating care at a low-barrier-to-access program (LBAP) by describing the proportion with human immunodeficiency virus (HIV), hepatitis B and C virus (HBV, HCV), syphilis, gonorrhea, and chlamydia and determining rates of treatment and/or linkage to care. METHODS: We reviewed the records of patients who completed an intake visit at an LBAP in Boston, MA during the first 9 months after implementation of a standardized intake laboratory panel (January 30, 2017-September 30, 2017). RESULTS: Among 393 patients initiating care, 84.7% (n = 333) completed at least 1 screening test. Baseline rates of HIV (9/393, 2.3%), current or past HCV (151/393, 38.4%), and chronic HBV (2/393, 0.5%) were high. Sixty-one new, active infections were identified through screening, including 1 HIV, 3 syphilis, 4 gonorrhea, 3 chlamydia, 1 chronic, and 1 acute HBV, and 48 cases of viremic HCV. Many patients were nonimmune to HBV (102/270, 37.8%) and HAV (112/255, 43.9%). Among new diagnoses, treatment was documented in 88% of bacterial infections and linkage occurred in 0/1 HIV, 2/2 HBV (100.0%), and 16/48 HCV (33.3%) cases. CONCLUSIONS: Patients initiating SUD care at an LBAP have substantial, unmet infection-related needs. Results justify the inclusion of comprehensive infection prevention, screening, and linkage-to-treatment protocols in LBAPs.
OBJECTIVE: To study the infection-related needs of patients with substance use disorders initiating care at a low-barrier-to-access program (LBAP) by describing the proportion with human immunodeficiency virus (HIV), hepatitis B and C virus (HBV, HCV), syphilis, gonorrhea, and chlamydia and determining rates of treatment and/or linkage to care. METHODS: We reviewed the records of patients who completed an intake visit at an LBAP in Boston, MA during the first 9 months after implementation of a standardized intake laboratory panel (January 30, 2017-September 30, 2017). RESULTS: Among 393 patients initiating care, 84.7% (n = 333) completed at least 1 screening test. Baseline rates of HIV (9/393, 2.3%), current or past HCV (151/393, 38.4%), and chronic HBV (2/393, 0.5%) were high. Sixty-one new, active infections were identified through screening, including 1 HIV, 3 syphilis, 4 gonorrhea, 3 chlamydia, 1 chronic, and 1 acute HBV, and 48 cases of viremic HCV. Many patients were nonimmune to HBV (102/270, 37.8%) and HAV (112/255, 43.9%). Among new diagnoses, treatment was documented in 88% of bacterial infections and linkage occurred in 0/1 HIV, 2/2 HBV (100.0%), and 16/48 HCV (33.3%) cases. CONCLUSIONS: Patients initiating SUD care at an LBAP have substantial, unmet infection-related needs. Results justify the inclusion of comprehensive infection prevention, screening, and linkage-to-treatment protocols in LBAPs.
Authors: Heather A Pines; Melanie L Rusch; Alicia Vera; Gudelia Rangel; Carlos Magis-Rodriguez; Steffanie A Strathdee Journal: Int J STD AIDS Date: 2015-01-22 Impact factor: 1.359
Authors: Philip J Peters; Pamela Pontones; Karen W Hoover; Monita R Patel; Romeo R Galang; Jessica Shields; Sara J Blosser; Michael W Spiller; Brittany Combs; William M Switzer; Caitlin Conrad; Jessica Gentry; Yury Khudyakov; Dorothy Waterhouse; S Michele Owen; Erika Chapman; Jeremy C Roseberry; Veronica McCants; Paul J Weidle; Dita Broz; Taraz Samandari; Jonathan Mermin; Jennifer Walthall; John T Brooks; Joan M Duwve Journal: N Engl J Med Date: 2016-07-21 Impact factor: 91.245
Authors: Elenore Patterson Bhatraju; Ellie Grossman; Babak Tofighi; Jennifer McNeely; Danae DiRocco; Mara Flannery; Ann Garment; Keith Goldfeld; Marc N Gourevitch; Joshua D Lee Journal: Addict Sci Clin Pract Date: 2017-02-28
Authors: Matthew R Golden; Richard Lechtenberg; Sara N Glick; Julie Dombrowski; Jeff Duchin; Jennifer R Reuer; Shireesha Dhanireddy; Santiago Neme; Susan E Buskin Journal: MMWR Morb Mortal Wkly Rep Date: 2019-04-19 Impact factor: 17.586
Authors: Jordana Laks; Jessica Kehoe; Natalija M Farrell; Miriam Komaromy; Jonathan Kolodziej; Alexander Y Walley; Jessica L Taylor Journal: Addict Sci Clin Pract Date: 2021-12-28
Authors: Karrin Weisenthal; Simeon D Kimmel; Jessica Kehoe; Marc R Larochelle; Alexander Y Walley; Jessica L Taylor Journal: Harm Reduct J Date: 2022-07-29